NVCR

NovoCure Limited

Price

$18.20

return (12m)

50.79%

p/e

-13.31

p/bv

5.85

DIVIDEND YIELD

0.00%

NVCR price

NovoCure

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NVCR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

11.66%

3 months

1.68%

1 year

50.79%

2 years

0.66%

5 years

-86.26%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals NVCR

Valuation

P/E

-13.31

Sector -4.38

Industry -4.38

P/BV

5.85

Sector 2.02

Industry 2.02

P/Revenue (PSR)

2.83

Sector -4.40

Industry -4.40

EV/EBITDA

-276.72

Sector -263.09

Industry -263.09

EV/EBIT

-164.04

Sector -702.90

Industry -702.90

P/EBITDA

-19.10

Sector -4.39

Industry -4.39

P/EBIT

-16.50

Sector -4.73

Industry -4.73

P/Total Assets

2.49

Sector 1.49

Industry 1.49

P/Net Current Assets

10.90

Sector -11.70

Industry -11.70

P/Working Capital

4.73

Sector -3.19

Industry -3.19

EPS

-1.28

Sector -2.14

Industry -2.14

BVPS

2.91

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

76.13%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-3.41%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-5.75%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-22.08%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-21.25%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.23

Sector 0.03

Industry 0.03

Profitability

ROE

-43.94%

Sector -65.14%

Industry -65.14%

ROA

-18.68%

Sector -65.53%

Industry -65.53%

ROIC

-27.00%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.89

Sector 2.90

Industry 2.90

Net Debt / EBITDA

39.08

Sector -6.07

Industry -6.07

Net Debt / EBIT

23.17

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.72

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.58

Sector -0.05

Industry -0.05

Equity/Assets

0.43

Sector 0.41

Industry 0.41

Liabilities/Assets

0.57

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

5.50%

Sector -

Industry -

5Y Earnings CAGR

20.55%

Sector -

Industry -

Fundamentals NVCR

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NVCR NovoCure Limited	$18.20	50.54%	0.00%	-13.31	5.85	-43.94%	-21.25%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NVCR Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT NovoCure

NovoCure Limited

Average Investor10 user rating

4.0 (1 people)

United States

26 years

Founded: 2000

2015

Time since IPO - 11 years

1.023

Employees

NovoCure Limited (United States) is listed on the Nasdaq and has a market capitalization of $1.98 billion, with shareholders equity totaling $338.09 million.

The company employs approximately 1.023 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, NovoCure Limited reported $699.19 million in revenue, generating net income of $-148.57 million.

Key financial metrics include a P/E ratio of -13.31, a price-to-book (P/B) ratio of 5.85, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NVCR.

Market cap

$1.98 billion

Net worth

$338.09 million

$338,090,000.00

Assets

$795.19 million

$795,190,000.00

Total Shares Outstanding

116.00 million

116,000,000

Average Daily Trading Volume

$1.69 million

$1,693,996.00

Sector

Health Care

Industry

Biotechnology

NVCR

NVCR revenue and profits

Financial Results NVCR

DRAG THE FRAME TO SEE MORE DATA

NVCR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of NovoCure (NVCR) today?

A cotação de NovoCure (NVCR) hoje está em US$ 18.20, com uma variação de 50.79% em relação ao último ano. A cotação de NovoCure (NVCR) iniciou o ano negociando na casa dos US$ 12.93 e hoje está em US$ 18.20. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de NovoCure (NVCR) e dados de ações do Ibovespa e mercados internacionais.

Quando NovoCure (NVCR) paga dividendos?

NovoCure (NVCR) não distribuiu dividendos no último ano.

Is NovoCure (NVCR) a good investment?

Atualmente, NovoCure (NVCR) está cotada a US$ 18.20, com um P/L de -13.31, representando um desvio de -2,688% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 50.79 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 50.79%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy NovoCure (NVCR) stock?

Investir em ações de NovoCure (NVCR) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of NovoCure (NVCR) yield today?

A rentabilidade de NovoCure (NVCR) foi de 11.66% no último mês, 50.79% no último ano e -86.26% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de NovoCure (NVCR) hoje, o investimento total seria de US$ 1,820.00, com base na cotação atual de US$ 18.20.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 2,744.38
Em 5 anos: US$ 250.07
Em 10 anos: US$ 1,820.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NVCR

NovoCure Limited

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NVCR

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING NVCR WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT NovoCure

NovoCure Limited

United States

26 years

2015

1.023

PROFIT X PRICE NVCR

Financial Results NVCR

NVCR cash flow

Asset, Revenue and Profit Growth - NVCR

NVCR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions